Zacks Highlights Peru Yield Recovery, but AVO's WAIT Thesis Unchanged

What happened

Zacks published an article on October 12, 2026, highlighting Mission Produce's rising avocado yields in Peru, expanding global distribution, and a stronger fourth-quarter sales outlook as drivers of an earnings recovery. The piece aligns with the company's recent performance, where Peruvian production recovery contributed to double-digit volume growth and margin improvement in fiscal 2025. However, the article does not provide new financial disclosures or strategic updates beyond what is already reflected in the latest 10-K and the pending Calavo Growers acquisition. Mission's stock has remained rangebound near $13, trading at approximately 8.3x EV/EBITDA and 25x earnings, leaving little room for multiple expansion absent visible merger synergies. The core investment debate remains unchanged: whether the Calavo deal closes on time and delivers its $25 million synergy target, rather than the Peru business alone.

Implication

Investors should treat the Zacks article as a reiteration of favorable but already-known operational trends, not a new catalyst. The Peru business is important for supply diversification and margin stability, but Mission's valuation already assumes sustained volume growth and stable per-unit margins. The more material driver of upside or downside over the next 6-12 months is the Calavo acquisition, which carries regulatory and integration risk. Until there is concrete progress on merger closing or the stock pulls back toward $11.00, the risk-reward is unattractive relative to the crowded "global avocado leader" narrative. Monitoring points include quarterly EBITDA margin, tariff developments, and any updates on the Calavo timeline.

Thesis delta

No change to the fundamental thesis. The Zacks article confirms the Peru yield recovery already captured in the fiscal 2025 results and master report, but adds no new information that would alter the WAIT rating or valuation. The core assumptions of mid-single-digit volume growth and stable margins remain intact, and the key swing factor remains the Calavo merger outcome.